Amneal Pharmaceuticals, Inc. (AMRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 300M 600M 900M Q3 '24: 702.5M Q4 '24: 730.5M Q1 '25: 695.4M Q2 '25: 724.5M Q3 '25: 784.5M Q4 '25: 814.3M Q1 '26: 722.5M Q2 '26: 796.2M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 150M 300M 450M Q3 '24: 269.6M Q4 '24: 262.9M Q1 '25: 255.9M Q2 '25: 286.3M Q3 '25: 274M Q4 '25: 297.2M Q1 '26: 320.1M Q2 '26: 334.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Income Quarterly

0 50M 100M 150M Q3 '24: 88.8M Q4 '24: 75.8M Q1 '25: 100.3M Q2 '25: 111.4M Q3 '25: 70.3M Q4 '25: 112M Q1 '26: 141.8M Q2 '26: 129.8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-50M -25M 0 25M 50M 75M Q3 '24: -156K Q4 '24: -31.1M Q1 '25: 12.2M Q2 '25: 22.4M Q3 '25: 2.4M Q4 '25: 35.1M Q1 '26: 62.3M Q2 '26: 57.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 200M 400M 600M Q3 '24: 432.9M Q4 '24: 467.6M Q1 '25: 439.5M Q2 '25: 438.3M Q3 '25: 510.5M Q4 '25: 517.1M Q1 '26: 402.4M Q2 '26: 461.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-50M 0 50M 100M 150M Q3 '24: 141.8M Q4 '24: 118.1M Q1 '25: 7.4M Q2 '25: 83.8M Q3 '25: 118.5M Q4 '25: 130.3M Q1 '26: -26.7M Q2 '26: -21.2M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-100M -50M 0 50M 100M 150M Q3 '24: 124.8M Q4 '24: 102.9M Q1 '25: -5.8M Q2 '25: 61M Q3 '25: 106.2M Q4 '25: 108.5M Q1 '26: -34.9M Q2 '26: -51.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '24: 307.3M Q2 '24: 319M Q3 '24: 309.6M Q1 '25: 324M Q2 '25: 322.4M Q3 '25: 324.8M Q1 '26: 328.9M Q2 '26: 328.1M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.90 -0.60 -0.30 0.00 0.30 0.60 0.90 Q3 '24: -0.85 Q4 '24: -0.38 Q1 '25: -0.04 Q2 '25: 0.01 Q3 '25: 0.02 Q4 '25: 0.23 Q1 '26: 0.38 Q2 '26: 0.49 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.